Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know

Company Overview - Ultragenyx (RARE) is expected to report a year-over-year increase in earnings driven by higher revenues for the quarter ended September 2025, with a consensus outlook indicating a quarterly loss of $1.23 per share, reflecting a +12.1% change from the previous year [1][3] - Revenues are anticipated to reach $167.55 million, representing a 20.1% increase compared to the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 0.43% lower over the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4] - The Most Accurate Estimate for Ultragenyx is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -12.47%, suggesting a bearish outlook from analysts [12] Earnings Surprise History - In the last reported quarter, Ultragenyx was expected to post a loss of $1.27 per share but actually reported a loss of -$1.17, achieving a surprise of +7.87% [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Vertex Pharmaceuticals (VRTX) is expected to report earnings of $4.55 per share for the same quarter, indicating a year-over-year change of +3.9% and revenues of $3.04 billion, up 9.7% from the previous year [18][19] - Vertex has an Earnings ESP of +0.57% and a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [19][20]